

Supplemental Table 1. Baseline characteristics of diabetic subjects according to the use of lipid-lowering agents

Characteristic	Lipid-lowering agent non-user (n=342)	Lipid-lowering agent user (n=297)	P value
Age, yr ^a	55.11±11.55	60.20±9.95	<0.001
BMI, kg/m ²	25.21±3.80	25.89±3.46	NS
WC, cm ^a	86.41±9.49	89.29±9.33	<0.001
WHR ^a	0.90±0.06	0.92±0.05	<0.001
Glucose at 0 min, mg/dL	137.65±46.66	132.86±44.77	NS
Glucose at 90 min, mg/dL	238.78±86.12	237.94±79.21	NS
A1c, %	7.59±1.73	7.65±1.33	NS
C-peptide at 0 min, µg/L	2.52±4.69	2.58±1.38	NS
C-peptide at 90 min, µg/L	6.79±3.16	7.19±6.04	NS
Insulin at 0 min, µIU/mL ^b	8.00 (1.00-58.49)	9.25 (2.32-81.76)	0.002
Insulin at 90 min, µIU/mL	53.22 (3.23-350.00)	50.88 (2.77-81.76)	NS
Cholesterol, mg/dL ^a	190.20±43.05	164.84±76.87	<0.001
TG at 0 min, mg/dL	125.00 (39.00-2,010.00)	125.50 (33.00-1,159.00)	NS
TG at 90 min, mg/dL	153.00 (37.00-2,220.00)	152.50 (42.00-1,072.00)	NS
HDL-C ^a	70.17±38.35	56.96±27.82	<0.001
LDL-C ^a	89.94±42.88	74.90±35.23	<0.001
HOMA-IR ^c	2.50 (0.25-25.44)	2.87 (0.38-44.61)	0.011
HOMA-β ^b	46.69 (3.85-586.44)	53.68 (-1522.00-2,433.60)	0.004
IGI	8.31 (-334.89-475.65)	7.20 (-640.80-1,251.00)	NS
T2D, %	79	91	

Subjects were further classified into 2 groups according to drug history (lipid-lowering agent non-user group and lipid-lowering agent user group). The patients' demographic and laboratory data are summarized in Supplemental Table 1. Among the enrolled subjects, 50% and 27% of the T2D and IFG patients have taken lipid-lowering drugs, respectively. Total cholesterol, HDL-C, and LDL-C were significantly higher in subjects in the lipid-lowering agent non-user group. WC, WHR, and HOMA-IR were statistically lower in the lipid-lowering agent non-user group. Fasting and postprandial glucose and TG were not different between the 2 groups.

BMI, body mass index; NS, not significant; WC, waist circumference; WHR, waist/hip ratio; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostatic model assessment of pancreatic β-cell function; IGI, insulinogenic index, T2D, type 2 diabetes; IFG, impaired fasting glucose.

^aP≤0.001, ^bP≤0.01, ^cP≤0.05.